Michael G. Fradley, MD, discusses real-world data on atrial fibrillation incidence and its cardiovascular and health care impact in CLL.
Back
Assessing AFib Burden and BTK Inhibitor Effects in CLL/SLL
Michael G. Fradley, MD, and colleagues spotlight the impact of AFib and BTK inhibitor selection in patients with CLL or SLL.
Assessing AFib Burden and BTK Inhibitor Effects in CLL/SLL
Episodes
All
All
Atrial fibrillation was associated with real-world cardiovascular and health care resource utilization burden in CLL/SLL.
Advertisement
Advertisement
Trending on OncLive
1
FDA Clears TumorSight Risk, an MRI-Derived AI Recurrence Tool for HR+, HER2– Breast Cancer
2
FDA Approves Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
3
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
4
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
5